The University of Nebraska Medical Center and Nebraska Medicine is involved in a clinical research study to test the safety and effectiveness of a possible COVID-19 vaccine for adults.
For this study, the medical center is working with the COVID-19 Prevention Network (COVPN), formed by the National Institute of Allergy and Infectious Diseases (NIAID) at the US National Institutes of Health to respond to the global pandemic.
Diana Florescu, MD, a professor and infectious diseases specialist in the UNMC Department of Internal Medicine, is leading the Phase 3 clinical study at UNMC.
“We are grateful and excited that UNMC was chosen as a site for this important work. We hope that this SARS CoV-2 vaccine will prevent the disease.”
Diana Florescu, MD
This study is what is called a randomized study, which means some people will be given the actual study vaccine drug and some will get a version that does not have any medication. The study involves two shots over the course of three weeks with four additional follow-up visits the first year and two follow-up visits the second year.
The study is looking for people who are:
- 19 years of age and older;
- Medically stable, with no changes to medications in the past two months;
- Have NOT had COVID-19/Corona Virus; and are
- NOT pregnant, breastfeeding or planning to become pregnant over the next four months.
If you are interested in enrolling, click the ‘Register Now’ button at the top of the page. IRB# 727.20.CB